miRNA diagnostics

The blood-based test, called Melaseq, measures 38 circulating microRNAs that regulate processes that melanoma cells undergo as they become malignant.

Priorities for Q3 include the continued buildup of a commercial launch for the company's BarreGEN test. The firm has started a second clinical validation study for the test.

The firm has collected evidence supporting the use of its PancraGen to providing the same molecular information for samples from biliary strictures and solid pancreatic lesions as it has done for years in pancreatic cyst fluid.

A 19-miRNA panel showed high sensitivity and specificity for differentiating benign and malignant thyroid nodules.

The company beat the analysts' average estimate on the top line but missed it on the bottom line as it posted a net loss of $3.2 million.

The payor published positive medical policy coverage for the ThyGenX and ThyraMir assays for thyroid nodules deemed indeterminate by standard cytopathological analysis.

The technology will measure cancer-associated miRNAs using optical amplification with quantum dots and photonic crystals.

The Singapore-based firm has established a US subsidiary and named distributors to sell its products across Europe, the Middle East, and Asia.

The French firm said that the funds will go toward international development and the marketing of the company's autoimmunity, allergy, and theranostic products. 

This Week in Science

In Science this week: DNA Fountain for storing data in DNA, and more.

Pages

Researchers are refining a tool to predict a woman's risk of developing breast cancer, according to the Guardian.

According to Stat News, the partial government shutdown in the US could soon affect the ability of the Food and Drug Administration to review new drugs.

In PNAS this week: gypsy moth genome sequenced, phylogenomic analysis of Polyneopterans, and more.

CNN reports that people's genes tend to have a greater influence on their risk of developing disease than their environment, but it varies by phenotype.